Navigation Links
Reportlinker Adds Biomarkers - Technologies, Markets and Companies
Date:6/3/2010

ral strategies 27

Table 2 2: Viral vs cellular targets for discovery of antivirals 28

Table 2 3: Viruses amenable to antisense oligonucleotides 39

Table 2 4: Inhibition of viral replication by RNAi 42

Table 3 1: Types of vaccines for viral diseases 46

Table 4 1: Role of nanobiotechnology in virology 53

Table 5 1: Methods of delivery of antiviral agents 59

Table 5 2: Role of nanotechnology for improving delivery of antivirals 64

Table 5 3: Commercially available liposomal antiviral vaccines 65

Table 6 1: SWOT of monoclonal antibodies 69

Table 6 2: SWOT of agents that prevention viral entry into cells 70

Table 6 3: SWOT of drugs interfering with intracellular replication 70

Table 6 4: SWOT of protease inhibitors 70

Table 6 5: SWOT of integrase inhibitors 70

Table 6 6: SWOT of maturation inhibitors 70

Table 6 7: SWOT of neuraminidase inhibitors 71

Table 6 8: SWOT of targeting Toll-like receptors (TLRs) 71

Table 6 9: SWOT of topical antivirals agents against viral infections 71

Table 6 10: SWOT of gene therapy, antisense oligonucleotides, RNAi 71

Table 6 11: SWOT of vaccines 71

Table 6 12: SWOT of NanoViricides 72

Table 7 1: Anti-influenza approaches 79

Table 7 2: Antiviral drugs used for influenza 79

Table 8 1: Drugs in clinical development for HI
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Reportlinker Adds Future of Red Biotechnology in China
2. Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration
3. Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)
4. Reportlinker Adds SNP Genotyping and Analysis Markets
5. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
6. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
7. Reportlinker Adds Biotechnology Instrumentation - International Market Trends
8. Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective
9. Reportlinker Adds Pharmacodynamic Assays
10. Reportlinker Adds Neurostimulation - A Global Market Perspective
11. Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... South Carolina (PRWEB) May 01, 2015 ... system services, is extremely proud to announce that for ... been named as a winner of a Queen’s Award ... success for the design and manufacture of a unique ... is the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... DIEGO , April 30, 2015   Tamir ... announced today an update on its Ebola antiviral therapy ... Tamir,s leading candidates, TMR004, is currently being evaluated and ... of the battle against Ebola. During the first quarter ... And Leadership Meeting To Accelerate The Evaluation of Potential ...
(Date:4/30/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... commenced an underwritten public offering of its common stock.  ... 30-day option to purchase up to an additional 15 ... the public offering. The offering is subject to market ... whether or when the offering may be completed, or ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Lixte,Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) today ... Bulletin Board under,the Symbol LIXT. Commenting on this ... "We believe that being a publicly traded company will,enable ... to us as,a private company. Having access to the ...
... of Cervical ... Cancer Risk, ... it has entered into an agreement to exclusively,license the Human Papillomavirus ... measurement of high-risk HPV types using,DNA-based detection. Quantovir is believed to ...
... MGCD0103,s Orphan Drug, Designation for the Treatment of ... BOULDER, Colo. and MONTREAL, Sept. 24 ,Pharmion Corporation ... MYG) today,announced that the European Medicines Agency (EMEA) ... deacetylase (HDAC),inhibitor, as an Orphan Medicinal Product for ...
Cached Biology Technology:Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 2Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 3Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 4Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 2Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 3Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 4
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... a mashup of monster movies, but palaeontologists have discovered evidence ... killing that took place 4 million years ago. ... careful, forensic-style analysis of bite marks on an otherwise well-preserved ... reconstructed the events that led to the death of the ...
... years of satellite data have found that the amount of ... the last three decades. Most of the increase has occurred ... increase in tropical regions. The new analysis shows, ... degrees a line that runs through central Texas in ...
... heart-healthy, essential omega-3 fatty acid is about to improve ... advance will move biotechnology onto the average consumer,s daily ... deliver positive environmental impacts and increase production to feed ... on Horizon , Recently, the U.S. Food and Drug ...
Cached Biology News:Jaws -- 4 million BC 2UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 2UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 3UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 4New biotech advance to add heart healthy omega-3s to US diet 2
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Request Info...
Candida (IgG) -Ab EIA Sample Size: 5 l...
... The Oxidized LDL Competitive ELISA is ... in the sample competes with a fixed amount ... for the binding of the biotin- labeled specific ... 25 l The Oxidized LDL Competitive Enzyme-Linked ...
Biology Products: